Peat Tyler J, Edmondson Elijah F, Miller Margaret A, DuSold Dee M, Ramos-Vara José A
1 Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA.
2 NCI, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Vet Pathol. 2017 Jul;54(4):588-594. doi: 10.1177/0300985817698211. Epub 2017 Mar 27.
Pax8, napsin A, and CD10 are useful immunohistochemical markers of human renal cell carcinoma (RCC); however, their diagnostic utility in canine RCC is unclear. Forty formalin-fixed paraffin-embedded renal cell carcinomas from dogs (15 papillary, 12 solid, and 13 tubular) and 10 metastases were evaluated for expression of Pax8, napsin A, and CD10. Thirty-nine (98%), 24 (60%), and 19 (50%) tumors expressed Pax8 (nuclear labeling), napsin A (cytoplasmic labeling), and CD10 (cytoplasmic and membranous labeling), respectively. Pax8 was expressed in 92% of solid, 100% of papillary, and 100% of tubular tumors. Napsin A was expressed in 58% of solid, 60% of papillary, and 62% of tubular RCC. CD10 was expressed in 33% of solid, 47% of papillary, and 62% of tubular RCC. Pax8 was expressed in 80% of the metastatic tumors, napsin A in 60%, and CD10 in 50%. Additionally, Pax8 immunoreactivity was stronger overall than that of napsin A or CD10. In summary, Pax8 is a more sensitive marker than napsin A or CD10 for primary and metastatic canine RCC; its nuclear and more intense reactivity also makes it easier to interpret. Tubular and papillary RCCs were more likely than solid RCC to express all 3 markers. These findings highlight the utility of Pax8 as an immunohistochemical marker in diagnosing all major subtypes of canine primary and metastatic renal cell carcinoma.
PAX8、 napsin A和CD10是人类肾细胞癌（RCC）有用的免疫组化标志物；然而，它们在犬RCC中的诊断效用尚不清楚。对40例来自犬的福尔马林固定石蜡包埋肾细胞癌（15例乳头状、12例实性和13例管状）和10例转移瘤进行了PAX8、 napsin A和CD10表达评估。39例（98%）、24例（60%）和19例（50%）肿瘤分别表达PAX8（核标记）、napsin A（胞质标记）和CD10（胞质和膜标记）。PAX8在92%的实性肿瘤、100%的乳头状肿瘤和100%的管状肿瘤中表达。Napsin A在58%的实性、60%的乳头状和62%的管状RCC中表达。CD10在33%的实性、47%的乳头状和62%的管状RCC中表达。PAX8在80%的转移瘤中表达，napsin A在60%中表达，CD10在50%中表达。此外，PAX8免疫反应性总体上比napsin A或CD10更强。总之，对于原发性和转移性犬RCC，PAX8是比napsin A或CD10更敏感的标志物；其核反应性更强也使其更容易解释。管状和乳头状RCC比实性RCC更可能表达所有3种标志物。这些发现突出了PAX8作为免疫组化标志物在诊断犬原发性和转移性肾细胞癌所有主要亚型中的效用。
